Evidence map›Paper›PMID 25505610›Full record

ArticlePharmacology research & perspectives2014

Involvement of S1P1 receptor pathway in angiogenic effects of a novel adenosine-like nucleic acid analog COA-Cl in cultured human vascular endothelial cells.

Junsuke Igarashi, Takeshi Hashimoto, Yasuo Kubota, Kazuyo Shoji, Tokumi Maruyama, Norikazu Sakakibara, Yoh Takuwa, Yoshihiro Ujihara, Yuki Katanosaka, Satoshi Mohri and 8 more

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Junsuke IgarashiDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Takeshi HashimotoDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Yasuo KubotaDepartment of Dermatology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Kazuyo ShojiDepartment of Dermatology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Tokumi MaruyamaKagawa School of Pharmaceutical Sciences, Tokushima Bunri University 1314-1 Shido, Sanuki, Kagawa, 769-2193, Japan.
Norikazu SakakibaraKagawa School of Pharmaceutical Sciences, Tokushima Bunri University 1314-1 Shido, Sanuki, Kagawa, 769-2193, Japan.
Yoh TakuwaDepartment of Cardiovascular Physiology, Kanazawa University School of Medicine 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan.
Yoshihiro UjiharaDepartment of Physiology, Kawasaki Medical School 577 Matsushima, Kurashiki, 701-0192, Japan.
Yuki KatanosakaDepartment of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Shitada-Cho 2-5-1, Kita-Ku, Okayama, 700-0914, Japan.
Satoshi MohriDepartment of Physiology, Kawasaki Medical School 577 Matsushima, Kurashiki, 701-0192, Japan.
Keiji NaruseDepartment of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Shitada-Cho 2-5-1, Kita-Ku, Okayama, 700-0914, Japan.
Tetsuo YamashitaDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Ryuji OkamotoDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Katsuya HiranoDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Hiroaki KosakaDepartment of Cardiovascular Physiology, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Maki TakataDepartment of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Ryoji KonishiDepartment of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Ikuko TsukamotoDepartment of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University 1750-1 Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Kagawa University · JPKawasaki Medical School · JPOkayama University · JPTokushima Bunri University · JPKanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COA-Cl (2Cl-C.OXT-A) is a recently developed adenosine-like nucleic acid analog that promotes angiogenesis via the mitogen-activated protein (MAP) kinases ERK1/2. Endothelial S1P1 receptor plays indispensable roles in developmental angiogenesis. In this study, we examined the functions of S1P1 in COA-Cl-induced angiogenic responses. Antagonists for S1P1, W146, and VPC23019, substantially but still partly inhibited the effects of COA-Cl with regard to ERK1/2 activation and tube formation in cultured human umbilical vein endothelial cells (HUVEC). Antagonists for adenosine A1 receptor and purinergic P2Y1 receptor were without effect. Genetic knockdown of S1P1 with siRNA, but not that of S1P3, attenuated COA-Cl-elicited ERK1/2 responses. The signaling properties of COA-Cl showed significant similarities to those of sphingosine 1-phosphate, an endogenous S1P1 ligand, in that both induced responses sensitive to pertussis toxin (Gα i/o inhibitor), 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM), (calcium chelator), and PP2 (c-Src tyrosine kinase inhibitor). COA-Cl elevated intracellular Ca(2+) concentration and induced tyrosine phosphorylation of p130Cas, a substrate of c-Src, in HUVEC. COA-Cl displaced [(3)H]S1P in a radioligand-binding competition assay in chem-1 cells overexpressing S1P1. However, COA-Cl activated ERK1/2 in CHO-K1 cells that lack functional S1P1 receptor, suggesting the presence of additional yet-to-be-defined COA-Cl target in these cells. The results thus suggest the major contribution of S1P1 in the angiogenic effects of COA-Cl. However, other mechanism such as that seen in CHO-K1 cells may also be partly involved. Collectively, these findings may lead to refinement of the design of this nucleic acid analog and ultimately to development of small molecule-based therapeutic angiogenesis.

Indexed as

Angiogenesisendothelial cellsnucleic acidreceptorsS1P1 receptorssignal transductionsphingosine 1-phosphate

Identifiers

PMID25505610
PMCPMC4186426
OpenAlexW2078821732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.